ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / ICCM / insiders
CODX (29) AMIX (34) BJDX (38) XAIR (30) ⌘ Pro Terminal β†’

IceCure Medical Ltd. (ICCM) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$0.84 -3.14% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.83

IceCure Medical Ltd. (ICCM) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E β€’ RED ALERT Cap $3.0M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ICCM Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is ICCM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, IceCure Medical Ltd. (NASDAQ: ICCM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $0.84 (-3.14% 1D, market cap $3.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ICCM ranks #706 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does ICCM compare to CODX and AMIX in the Health Care sector?
β–Ό

Within the Health Care sector (Medical/Dental Instruments), ICCM carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of 36.3%, and ROIC of -35.0%. By comparison, CODX (Co-Diagnostics Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $3.2M) and AMIX (Autonomix Medical Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $3.5M). Among the 5-stock peer group, XAIR leads on earnings multiple (112.1x) while ICCM leads on capital efficiency (-35.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ICCM?
β–Ό

Per ICCM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001584371), IceCure Medical Ltd. generated $3.4M in revenue (+2.7% YoY), -$15.1M in net income, and -$14.6M in free cash flow against $13.9M in total assets and $13.0K in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.83 (-0.76%)🧬 Disciplined Float (+0.72% YoY Shares)βš™οΈ Cash Engine: 6/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (33/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510033
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk D
Cash (6)Whales (3)SEC (10)Macro (9)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-10.7% Base Target
$25 Bull$1 Base$1 Bear
πŸ“¬ FREE ICCM RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for ICCM)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (33/100 Composite)
πŸ” WHY ICCM SCORES 33/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 5/9

β–² #2 Bullish Driver: Macro Regime Fit+9/20 pts (27% of score)

FRED Regime Γ— Technicals: 2% of 52W Range β€’ RSI-14 at 25.1 (OVERSOLD (<32))

β–Ό #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
41
Grade D$1.10-4.5% Next Q
Q2 (-2Q)
38
Grade E$1.05-1.9% Next Q
Q3 (-1Q)
36
Grade E$1.03-18.4% Next Q
Current
33
Grade E$0.84-8.9% Hist 90D Ξ±
Trajectory: D (41) β†’ E (33)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a ICCM Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While ICCM currently carries a cautious 33/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.60) and Max Pain ($0.88) forces dealer call-delta covering toward $24.66.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ICCMβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œICCM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 33%NO 67%Trade / Inspect Odds β†’
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

ICCM Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (ICCM)

No recent open-market Form 4 cluster sales or emergency dumps flagged on ICCM. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ICCM)

  • βœ“Walkthrough of ICCM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
ICCM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -90.48%πŸ›‘οΈ HOLDING TREND SUPPORT
2026-11-03O $0.96H $0.96L $0.84C $0.84VOL 50.3K
SUP: $0.49SMA50: $1.60SMA200: $7.73
$22.99$16.98$10.97$4.96$-1.04SUP $0.49$0.842026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ICCM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ ICCM Butterfly Map β†’ + Track ICCM β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +2.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ICCM today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for ICCM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ICCM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ICCM)

Health Care Rank #706 of 1015 βš”οΈ CODX vs ICCM Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (ICCM vs. CODX, AMIX, BJDX, XAIR)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, IceCure Medical Ltd. (ICCM) ranks #706 by composite RQD confidence (33/100, grade E) and #977 by equity capitalization ($3.0M). Within this direct 5-issuer industry benchmark cohort, XAIR leads on earnings valuation at 112.1x trailing P/E, while ICCM leads on capital efficiency and profitability with -35.0% ROIC and 36.3% gross margin. BJDX currently holds the highest overall quantitative score in the immediate peer group at 38/100 (D-) compared with ICCM at 33/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ICCM ACTIVE
IceCure Medical Ltd.
E 33/100 β€” 36.3% -35.0% -3.14% $3.0M Benchmark Subject
CODX
Co-Diagnostics Inc.
E 29/100 β€” 64.3% -35.0% -3.65% $3.2M /codx-vs-iccm β†’
AMIX
Autonomix Medical Inc.
E 34/100 β€” β€” -35.0% -7.18% $3.5M /amix-vs-iccm β†’
BJDX
Bluejay Diagnostics Inc.
D- 38/100 β€” β€” -35.0% -4.74% $2.5M /bjdx-vs-iccm β†’
XAIR
Beyond Air Inc.
E 30/100 112.1x 3.3% -35.0% -1.34% $3.7M /xair-vs-iccm β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001584371 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), IceCure Medical Ltd. (ICCM) reported GAAP revenue of $3.4M (+2.7% vs. FY2024 revenue of $3.3M , and +4.6% cumulative change since FY2023) , GAAP net income of -$15.1M, operating cash flow of -$14.6M, and free cash flow of -$14.6M (-15.6% YoY). On the balance sheet, ICCM closed FY2025 with $13.9M in total assets against $13.0K in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $3.4M -$15.1M -$14.6M -$14.6M $13.9M $13.0K
FY2024 (FY) 2024-12-31 $3.3M -$15.3M -$12.6M -$12.6M $12.6M $161.0K
FY2023 (FY) 2023-12-31 $3.2M -$14.7M -$12.6M -$12.6M β€” β€”

3. ICCM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ICCM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, IceCure Medical Ltd. (NASDAQ: ICCM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $0.84 (-3.14% 1D, market cap $3.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ICCM ranks #706 in composite RQD confidence.

How does ICCM compare to CODX and AMIX in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), ICCM carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of 36.3%, and ROIC of -35.0%. By comparison, CODX (Co-Diagnostics Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $3.2M) and AMIX (Autonomix Medical Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $3.5M). Among the 5-stock peer group, XAIR leads on earnings multiple (112.1x) while ICCM leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ICCM?

Per ICCM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001584371), IceCure Medical Ltd. generated $3.4M in revenue (+2.7% YoY), -$15.1M in net income, and -$14.6M in free cash flow against $13.9M in total assets and $13.0K in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ICCM trading relative to its 50-day, 200-day, and 52-week technical levels?

ICCM last traded at $0.84 (-3.14% on volume of 54,366 shares), positioning the stock -47.50% below its 50-day simple moving average ($1.60) and -89.13% below its 200-day simple moving average ($7.73). Across its 52-week range of $0.82 to $23.49, ICCM sits at the 0.1% percentile with a 14-day RSI of 25.1 (OVERSOLD (<32)) and an implied next-earnings move of Β±12.5% ($1.00 to $0.94).

Direct Sub-Reports: ICCM RQD Cockpit ICCM 12M Forecast ICCM Earnings & Move ICCM Dividends & DRIP ICCM Insiders & 13F ICCM Whale Options ICCM Profit Sankey ICCM News & Why
ROARABLE RATING BRIEF β€’ RQD 33/100 (E) βœ“ SEC XBRL & RQD VERIFIED

ICCM β€” IceCure Medical Ltd.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

IceCure Medical Ltd. (ICCM) earns a live Roarable RQD composite score of 33/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.84 (-3.14% 1D, market capitalization $3.0M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 36.3%, operating margin of -60.0%, and free cash flow yield of β€”.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 5/9, and Debt/Equity of 0.00x.

2. Business Model, Unit Margins & SEC Financial Trajectory

IceCure Medical Ltd. (ICCM) is a NASDAQ-listed issuer in the Health Care sector, Medical/Dental Instruments industry,. Per the recent news wire, the company is engaged in a breast cancer study involving tumor freezing, with a headline reporting a 97.5% response rate at 12 months across 40 patients when combined with hormone therapy. FY 2025 revenue was $3.4M.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), IceCure Medical Ltd. (ICCM) reported $3.4M in annual revenue (up from $3.3M in FY2024, +2.7% YoY) and -$15.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($3.2M revenue, -$14.7M net income) through FY2025, ICCM scaled operating cash flow to -$14.6M and free cash flow to -$14.6M, backed by $13.9M in total assets against $13.0K in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (E β€’ RQD 33/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of β€” and institutional whale pillar of 3/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $0.82 – $23.49 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

A prospective investor should note that the absence of mapped links means this analysis cannot identify supplier or customer concentration from the provided data.

  • Key Question #1: Can ICCM sustain or expand its -60.0% operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $3.4M and free cash flow of -$14.6M, how will capital allocation balance growth reinvestment against $13.0K in total debt?
  • Key Question #3: How sensitive is ICCM's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ICCM Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for IceCure Medical Ltd. (ICCM) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to ICCM Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ICCM Bull vs. Bear Conversation Board β€” What's Your Call at $0.84?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ICCM 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ICCM:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
TA TapeReader_Pro RQD DEBATE OPENER β€’ Price Action & Volume Trader πŸ‚ BULLISH 🎯 Target: $1.01 (+16.1%)
πŸ“Œ Pinned Debate

Per the Roarable RQD rating, the balance sheet carries no debt in FY 2025 and cash rose to $8.9M, with Altman Z of 2.5 and Piotroski F

Picked up a starter position in ICCM in my $100K Virtual Cash book at $0.87. Per the Roarable RQD rating, the balance sheet carries no debt in FY 2025 and cash rose to $8.9M, with Altman Z of 2.5 and Piotroski F of 5/9.. Trading inside a $0.82–$23.49 52-week range with 0.0% FCF yield gives solid downside support if Medical/Dental Instruments multiples expand this quarter.

RetailWhale_TX πŸ‚ BULL

Both sides have a point here β€” ICCM's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

SH ShortSeller_Dan RQD DEBATE OPENER β€’ Forensic Short Bias 🐻 BEARISH 🎯 Target: $0.75 (-13.8%)
Spot @ $0.87

Per the SEC financials, FY 2025 free cash flow was -$14.6M on $3.4M revenue, and per the Roarable RQD rating ROIC is -35% with FCF yiel

Fading this rally in ICCM at $0.87. Per the SEC financials, FY 2025 free cash flow was -$14.6M on $3.4M revenue, and per the Roarable RQD rating ROIC is -35% with FCF yield of 0%.. With a beta of 1.0 and the stock sitting at $0.87 (52-wk range $0.82–$23.49), the easy multiple expansion is already priced in.

LIVE TAPE